Cervical Neuroendocrine Carcinoma
Associated Genetic Biomarkers
Cervical neuroendocrine carcinomas most frequently harbor alterations in MYC, TP53, RB1, SF3B1, and RGS13 .
MYC Amplification, TP53 c.217-c.1178 Missense, TP53 Mutation, TP53 Missense, and TP53 Exon 7 Mutation are the most common alterations in cervical neuroendocrine carcinoma .
There is 1 clinical trial for cervical neuroendocrine carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains cervical neuroendocrine carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
CDKN2A and HPV are the most frequent gene inclusion criteria for cervical neuroendocrine carcinoma clinical trials .
Bintrafusp alfa is the most common intervention in cervical neuroendocrine carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.